In an industry where a single failed trial can erase billions in value, Cytel isn't just offering analytics—they're selling statistical certainty. With $509M in annual revenue and 1,583 employees, this isn't a startup; it's a precision instrument for pharma's most critical decisions.

"Cytel doesn't just analyze data—they build statistical architectures that determine whether a drug survives to market."

The leadership team tells the story: Kevin Trimm (CPO) and Jonathan Burr (CCO) aren't just executives—they're operators who understand that life science data isn't about dashboards, it's about regulatory submissions. With Massoud Toussi leading Real World Evidence, Cytel is positioning itself at the intersection of clinical trials and post-market surveillance.

• Enterprise DNA: 38% direct traffic proves deep client relationships
• Statistical specialization: Not just data science, but biostatistics
• Global footprint: Traffic from multiple undefined regions suggests international operations
• Talent density: 1,583 employees for $509M revenue = $321K revenue per employee